Stephen J Russell 1 , Mark J Federspiel 2 , Kah-Whye Peng 2 , Caili Tong 2 , David Dingli 1 , William G Morice 3 , Val Lowe 4 , Michael K O'Connor 4 , Robert A Kyle 5 , Nelson Leung 6 , Francis K Buadi 5 , S Vincent Rajkumar 5 , Morie A Gertz 5 , Martha Q Lacy 5 , Angela Dispenzieri 7
MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 10(11) TCID50 (50% tissue culture infectious dose) infectious units of MV-NIS. Both patients responded to therapy with M protein reduction and resolution of bone marrow plasmacytosis. Further, one patient experienced durable complete remission at all disease sites. Tumor targeting was clearly documented by NIS-mediated radioiodine uptake in virus-infected plasmacytomas. Toxicities resolved within the first week after therapy. Oncolytic viruses offer a promising new modality for the targeted infection and destruction of disseminated cancer.